LC
RXRX icon

Lindbrook Capital’s Recursion Pharmaceuticals RXRX Stock Holding History

Lindbrook Capital’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$8.83K Buy
1,670
+714
+75% +$5.21K ﹤0.01% 1708
2024
Q4 		$6.46K Buy
956
+246
+35% +$1.65K ﹤0.01% 1872
2024
Q3 		$4.68K Buy
710
+73
+11% +$523 ﹤0.01% 2039
2024
Q2 		$4.78K Buy
637
+392
+160% +$3.42K ﹤0.01% 2017
2024
Q1 		$2.44K Hold
245
– – ﹤0.01% 2170
2023
Q4 		$2.42K Sell
245
-207
-46% -$1.48K ﹤0.01% 2203
2023
Q3 		$3.46K Buy
452
+207
+84% +$2.06K ﹤0.01% 1930
2023
Q2 		$1.83K Buy
+245
New +$1.71K ﹤0.01% 2179
2022
Q4 		– Sell
-122
Closed -$1K – 2984
2022
Q3 		$1K Buy
+122
New +$1.24K ﹤0.01% 2470

Other funds holding RXRX

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Lindbrook Capital's RXRX Position: Q1 2025 in Review

Lindbrook Capital increased its Recursion Pharmaceuticals (RXRX) stake by 75% in Q1 2025, buying an estimated $5.21K and bringing the position to 1,670 shares worth $8.83K. The position accounts for ﹤0.01% of the portfolio, ranked #1708.

Lindbrook Capital first reported a position in RXRX in Q3 2022 and has held it in 9 quarters since. 336 funds tracked by Wall St. Rank hold RXRX as of Q1 2025.

  • Lindbrook Capital held 1,670 shares of Recursion Pharmaceuticals worth $8.83K as of Q1 2025.
  • Lindbrook Capital bought 714 Recursion Pharmaceuticals shares in Q1 2025, an estimated $5.21K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1708 holding.
  • Lindbrook Capital first reported a position in Recursion Pharmaceuticals in Q3 2022 and has held it in 9 quarters since.
  • 336 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.